Tags

Type your tag names separated by a space and hit enter

HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
Eur J Clin Invest. 2007 Nov; 37(11):852-9.EJ

Abstract

BACKGROUND

Statins reduce cardiomyocyte hypertrophy in animal models of hypertrophic cardiomyopathy, aortic banding and heart failure after myocardial infarction. We investigated the effect of the hydroxymethylglutaryl coenzyme A reductase inhibitor atorvastatin on left ventricular (LV) mass in patients with hypertrophic cardiomyopathy in a randomized placebo-controlled double-blind pilot study.

MATERIALS AND METHODS

Patients with hypertrophic cardiomyopathy were randomized to be treated once daily by atorvastatin 80 mg or placebo for nine months. LV mass was assessed by serial cardiac magnetic resonance imaging. LV systolic and diastolic function was determined by echocardiography. Markers of collagen metabolism and inflammation were also assessed.

RESULTS

Out of 78 screened patients with hypertrophic cardiomyopathy 28 (2 x 14) patients were eligible for randomization. Eleven patients in each group completed the study with cardiac magnetic resonance imaging assessments meeting the evaluation standards at baseline and at follow-up. Low-density lipoprotein cholesterol levels in the atorvastatin group decreased from 3.24 +/- 1.14 mmol L(-1) (125 +/- 44 mg dL(-1)) at baseline to 1.37 +/- 0.49 mmol L(-1) (53 +/- 19 mg dL(-1)) at follow-up (P < 0.001), but were unchanged in the placebo group. Baseline LV mass was 228 +/- 51 g in the placebo and 232 +/- 67 g in the atorvastatin group. The primary endpoint of change in LV mass from baseline to follow-up was 2 +/- 10% in the atorvastatin group versus 0 +/- 13% in the placebo group (P = NS). Parameters of LV volumes and diameters, systolic and diastolic function, and markers of collagen metabolism were also unchanged in both groups.

CONCLUSION

In patients with hypertrophic cardiomyopathy, this randomized placebo-controlled double-blind pilot study did not demonstrate an effect of 9-month treatment with atorvastatin 80 mg on LV mass reduction.

Authors+Show Affiliations

Medizinische Klinik und Poliklinik I, Kardiologie, Julius-Maximilians-Universität Würzburg, Josef-Schneider-Strasse 2, 97080 Würzburg, Germany. bauersachs_j@medizin.uni-wuerzburg.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17973781

Citation

Bauersachs, J, et al. "HMG CoA Reductase Inhibition and Left Ventricular Mass in Hypertrophic Cardiomyopathy: a Randomized Placebo-controlled Pilot Study." European Journal of Clinical Investigation, vol. 37, no. 11, 2007, pp. 852-9.
Bauersachs J, Störk S, Kung M, et al. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study. Eur J Clin Invest. 2007;37(11):852-9.
Bauersachs, J., Störk, S., Kung, M., Waller, C., Fidler, F., Hoyer, C., Frantz, S., Weidemann, F., Ertl, G., & Angermann, C. E. (2007). HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study. European Journal of Clinical Investigation, 37(11), 852-9.
Bauersachs J, et al. HMG CoA Reductase Inhibition and Left Ventricular Mass in Hypertrophic Cardiomyopathy: a Randomized Placebo-controlled Pilot Study. Eur J Clin Invest. 2007;37(11):852-9. PubMed PMID: 17973781.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study. AU - Bauersachs,J, AU - Störk,S, AU - Kung,M, AU - Waller,C, AU - Fidler,F, AU - Hoyer,C, AU - Frantz,S, AU - Weidemann,F, AU - Ertl,G, AU - Angermann,C E, PY - 2007/11/2/pubmed PY - 2008/3/29/medline PY - 2007/11/2/entrez SP - 852 EP - 9 JF - European journal of clinical investigation JO - Eur J Clin Invest VL - 37 IS - 11 N2 - BACKGROUND: Statins reduce cardiomyocyte hypertrophy in animal models of hypertrophic cardiomyopathy, aortic banding and heart failure after myocardial infarction. We investigated the effect of the hydroxymethylglutaryl coenzyme A reductase inhibitor atorvastatin on left ventricular (LV) mass in patients with hypertrophic cardiomyopathy in a randomized placebo-controlled double-blind pilot study. MATERIALS AND METHODS: Patients with hypertrophic cardiomyopathy were randomized to be treated once daily by atorvastatin 80 mg or placebo for nine months. LV mass was assessed by serial cardiac magnetic resonance imaging. LV systolic and diastolic function was determined by echocardiography. Markers of collagen metabolism and inflammation were also assessed. RESULTS: Out of 78 screened patients with hypertrophic cardiomyopathy 28 (2 x 14) patients were eligible for randomization. Eleven patients in each group completed the study with cardiac magnetic resonance imaging assessments meeting the evaluation standards at baseline and at follow-up. Low-density lipoprotein cholesterol levels in the atorvastatin group decreased from 3.24 +/- 1.14 mmol L(-1) (125 +/- 44 mg dL(-1)) at baseline to 1.37 +/- 0.49 mmol L(-1) (53 +/- 19 mg dL(-1)) at follow-up (P < 0.001), but were unchanged in the placebo group. Baseline LV mass was 228 +/- 51 g in the placebo and 232 +/- 67 g in the atorvastatin group. The primary endpoint of change in LV mass from baseline to follow-up was 2 +/- 10% in the atorvastatin group versus 0 +/- 13% in the placebo group (P = NS). Parameters of LV volumes and diameters, systolic and diastolic function, and markers of collagen metabolism were also unchanged in both groups. CONCLUSION: In patients with hypertrophic cardiomyopathy, this randomized placebo-controlled double-blind pilot study did not demonstrate an effect of 9-month treatment with atorvastatin 80 mg on LV mass reduction. SN - 0014-2972 UR - https://www.unboundmedicine.com/medline/citation/17973781/HMG_CoA_reductase_inhibition_and_left_ventricular_mass_in_hypertrophic_cardiomyopathy:_a_randomized_placebo_controlled_pilot_study_ L2 - https://doi.org/10.1111/j.1365-2362.2007.01877.x DB - PRIME DP - Unbound Medicine ER -